Great West Life Assurance Co. Can lowered its stake in Inogen, Inc (NASDAQ:INGN) by 0.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 48,926 shares of the medical technology company’s stock after selling 432 shares during the period. Great West Life Assurance Co. Can owned 0.23% of Inogen worth $4,666,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of INGN. Koch Industries Inc. increased its holdings in shares of Inogen by 19,485.8% in the second quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after purchasing an additional 653,747 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Inogen by 24.9% in the second quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock valued at $144,594,000 after purchasing an additional 301,737 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of Inogen by 77.4% in the second quarter. New York State Common Retirement Fund now owns 389,206 shares of the medical technology company’s stock valued at $37,138,000 after purchasing an additional 169,778 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Inogen by 91.8% in the second quarter. Goldman Sachs Group Inc. now owns 128,043 shares of the medical technology company’s stock valued at $12,217,000 after purchasing an additional 61,291 shares in the last quarter. Finally, Prudential Financial Inc. increased its holdings in shares of Inogen by 78.2% in the third quarter. Prudential Financial Inc. now owns 124,088 shares of the medical technology company’s stock valued at $11,801,000 after purchasing an additional 54,467 shares in the last quarter.

A number of brokerages recently weighed in on INGN. Leerink Swann reissued an “outperform” rating and issued a $120.00 price target (up previously from $115.00) on shares of Inogen in a report on Wednesday, November 8th. BidaskClub lowered shares of Inogen from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a report on Thursday, November 9th. Needham & Company LLC lifted their target price on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday, November 8th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $90.00 target price on shares of Inogen in a report on Tuesday, September 12th. Four investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $103.14.

In other news, EVP Byron Myers sold 35,000 shares of Inogen stock in a transaction on Friday, November 17th. The shares were sold at an average price of $116.77, for a total transaction of $4,086,950.00. Following the transaction, the executive vice president now directly owns 48,600 shares of the company’s stock, valued at $5,675,022. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Heath Lukatch sold 2,500 shares of Inogen stock in a transaction on Friday, December 1st. The stock was sold at an average price of $126.40, for a total transaction of $316,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 88,000 shares of company stock valued at $9,349,730 in the last ninety days. Company insiders own 5.31% of the company’s stock.

Shares of Inogen, Inc (INGN) opened at $118.21 on Friday. Inogen, Inc has a fifty-two week low of $62.69 and a fifty-two week high of $130.05. The company has a market cap of $2,460.00, a price-to-earnings ratio of 95.47, a price-to-earnings-growth ratio of 4.93 and a beta of 1.13.

Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm had revenue of $69.00 million during the quarter, compared to analyst estimates of $63.55 million. During the same quarter in the previous year, the business earned $0.25 EPS. The business’s quarterly revenue was up 26.8% compared to the same quarter last year. equities research analysts predict that Inogen, Inc will post 1.19 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Great West Life Assurance Co. Can Lowers Position in Inogen, Inc (INGN)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/09/great-west-life-assurance-co-can-lowers-position-in-inogen-inc-ingn.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.